MetaCap

Bambusa Therapeutics (BBTX) vs Odyssey Therapeutics (ODTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Odyssey Therapeutics is the larger company by market cap ($815.2 million vs $815.1 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BBTX+6.74%ODTX-13.20%
+16%+1%-15%
Oct 30, 20261 yearNov 20, 2026
BBTX+6.74%ODTX-13.20%
+8%-3%-14%
Oct 26, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BBTX versus ODTX key metrics
MetricBBTXODTX
Share price$16.00$16.96
Market cap$815.08M$815.23M
1-day change+2.89%-7.52%
EPS (TTM)$-1.73$-6.33
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
52-week high$17.65$29.05
52-week low$13.60$15.10
Distance from 52-week high-9.35%-41.62%
Analyst consensus—strong_buy
Avg. price target upside—+104.42%
Average volume359.41K329.31K
Shares outstanding50.94M48.07M
Employees26100
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Bambusa Therapeutics

BBTX stock →

Bambusa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops long-acting bispecific antibodies for the treatment of immunological and inflammatory disorders. The company develops BBT001 for Type 2 inflammatory dermatological conditions, including atopic dermatitis, chronic spontaneous urticaria, and prurigo nodularis.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 26 employees

About Odyssey Therapeutics

ODTX stock →

Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptor–associated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 100 employees

BBTX vs ODTX FAQ

Which is bigger, Bambusa Therapeutics or Odyssey Therapeutics?

Odyssey Therapeutics (ODTX) is larger, with a market capitalization of $815.23M compared with $815.08M for Bambusa Therapeutics (BBTX).

Are Bambusa Therapeutics and Odyssey Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons